74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Pfizer
Closed
SectorHealthcare
22.8 1.83
Overview
Share price change
24h
Min
22.23
Max
22.85
Income | -4.1B 411M |
|---|---|
Sales | 63M 18B |
P/E Sector Avg | 15.631 57.333 |
EPS | 0.63 |
Dividend yield | 7.8 |
Profit margin | 2.314 |
Employees | 81,000 |
EBITDA | -4.3B 2.5B |
Recommendations | Buy |
|---|---|
12 Months Forecast | +22.04% upside |
Dividend yield Sector Avg | 7.80% 2.63% |
|---|---|
Next Earnings | 29 Apr 2025 |
Next Dividend date | 13 Jun 2025 |
Next Ex Dividend date | 9 May 2025 |
Market Cap | -26B 126B |
|---|---|
Previous open | 20.97 |
Previous close | 22.8 |
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
Pfizer Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Pfizer Forecast
Price Target
By TipRanks
22.04% upside
12 Months Forecast
Average 27.8 USD 22.04%
High 32 USD
Low 23 USD
Based on 17 Wall Street analysts offering 12 month price targets forPfizer - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
